Adipokine Modulation in Endometrial Hyperplasia by Polyunsaturated Fatty Acids
- 1,
- 1,
- 1*
- 1Department of Pharmacology, JSS College of Pharmacy, Ooty, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, INDIA.
Published in Journal of Pharmacology and Pharmacotherapeutics
Correspondence: Praveen Thaggikuppe Krishnamurthy
Department of Pharmacology, JSS College of Pharmacy, Ooty, JSS Academy of Higher Education & Research, Ooty, The Nilgiris, Tamil Nadu, INDIA.
Email: praveentk@jssuni.edu.in
Copyright: © 2024 The Author(s). This is an open access article.
Published: Jan 1, 2024, Received: Mar 28, 2024, Accepted: May 9, 2024
Abstract
Background: Obesity is associated with a higher prevalence of endometrial hyperplasia, thereby increasing the risk of endometrial and ovarian cancers. The precise mechanisms linking obesity to endometrial hyperplasia remain unclear, but dysregulation of adipose tissue homeostasis is known to play a significant role. Hypertrophied adipocytes in obese individuals secrete various bioactive substances, including cytokines, growth factors, hormones, and metabolites. Additionally, hyperplastic adipocytes exhibit enhanced aromatase activity, leading to increased estrogen synthesis, which further promotes the development of endometrial hyperplasia. Purpose: The purpose of this study is to explore the anti-inflammatory and anti-proliferative activities of the poly unsaturated fatty acids. Methodology: An extensive literature survey has been performed to identify the role of adipokines and elevated endogenous estrogen levels in activating cell survival signaling pathways, such as PI3K/Akt/mTOR, MEK/ERK1, and JAK–STAT in endometrial cells and their possible role in Endometrial Hyperplasia. Further, the possible beneficial anti-inflammatory and anti-proliferative effects of polyunsaturated fatty acids (PUFAs) such as eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and arachidonic acid (AA) were explored. Results: Numerous studies suggest the beneficial role of dietary fats, such as EPA, DHA, and AA in modulating the growth of endometrium in obesity-induced endometrial hyperplasia. PUFAs can activate adenosine monophosphate-activated protein kinase (AMPK), which inhibits gluconeogenesis and lipogenesis. It also phosphorylates acetyl-CoA, leading to a decrease in malonyl-CoA, which inhibits mitochondrial CPT1. Additionally, AMPK activation promotes β-oxidation, and PPAR-γ mechanisms by down regulating the NF-kB pathway involved in endometrial hyperplasia. Conclusion: This review sheds light on the potential of PUFAs in mitigating estrogen synthesis, adipokine secretion, and endogenous aromatase activity in obesity induced endometrial hyperplasia. Furthermore, it critically evaluates the role and mechanisms of PUFAs in attenuating obesity-associated endometrial hyperplasia and reducing the risk of ovarian cancer.
Keywords
Subject
Readers Also Viewed
Pharmacogenomics Meets Generative AI: Transforming Clinical Trial Design with Large Language Models
Annisa Fatharani, Ali Alsayegh
Jan 1, 2026
Clinical Outcomes and Management of Post-varicocelectomy on Male Fertility: A Comprehensive Review
Mohammad Akbar Hossain
Jan 1, 2026
Knowledge, Attitude, and Practice on Digital Eye Strain Among Healthcare Students at a Private University in Northern Peninsular Malaysia
Lim Chin Hung, Subramani Parasuraman, Sam Aaseer Thamby
Jan 1, 2026